Suritozole, formerly known as MDL-26479, is an investigational cognition enhancer. It acts as a partial inverse agonist at the benzodiazepine receptor site on the GABAA ion channel complex, but does not have either anxiogenic or convulsant effects, unlike other BZD inverse agonists such as DMCM. It was investigated for the treatment of depression and Alzheimer's disease, but clinical development seems to have been discontinued. References: Robbins DK, Hutcheson SJ, Miller TD, Green VI, Bhargava VO, Weir SJ. Pharmacokinetics of MDL 26479, a novel benzodiazepine inverse agonist, in normal volunteers. Biopharm Drug Dispos. 1997 May;18(4):325-34. PubMed PMID: 9158880.

纯度：≥98%

CAS：110623-33-1